70
IASLC ATLAS OF ALK TESTING IN LUNG CANCER
Felip E, Gridelli C, Baas P, et al. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol. 2011;22:1507-1519. Gainor J, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273-4281. Garrido P, de Castro J, Concha Á et al. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol. 2012;14(5):338-339. Halling K, Schrijver I, Persons DL. Test verification and validation for molecular diagnostic assays. Arch Pathol Lab Med. 2012;136(1):11-13. Hirsch F, Yatabe Y, Dietel M, et al. ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in non-small cell lung carcinoma (NSCLC): an international consensus study. J Clin Oncol. 2013;31(May 20 Supplement):e22042. Huang D KD, Kotsakis A, et al. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics. 2013 Feb 20 [Epub ahead of print]. Hunt J. Molecular pathology in anatomic pathology practice: a review of basic principles. Arch Pathol Lab Med. 2007; 132(2):248-260. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13-17. Jin G, Jeon HS, Lee EB, et al. EML4-ALK fusion gene in Korean non-small cell lung cancer. J Korean Med Sci. 2012; 27(2):228-230. Jing X, Li QK, Bedrossian U, Michael CW. Morphologic and immunocytochemical performances of effusion cell blocks prepared using 3 different methods Am J Clin Pathol. 2013; 139(2):177-182. Jokoji R, Yamasaki T, ???2?WB??6??&??F????b??'????v?6?fVGW&R??6?2?B???V????7F?6?V?7G'??2W6VgV?f?"67&VV???r?bT??B????6?F?fR?V?rFV??6&6??????6??F????#?c2?"??cb?s????"??v?7GV&????W&fV7F??rF?Rf??R??VVF?R7?&FR6V??&??6??6?6W"7?F?F????#3?#?2??????W'"??6???6?&V?Wf?6R?bF?R?Wr?4?2?U%2?E2FV??6&6????6?76?f?6F?????6??F????#2"b?WV"?VB?b&??E?????W'"?????2???6??6???2?F????w??BW'6????VB?VF?6??R???V?r6?6W"??V?r6?6W"??vR?#3?"???3R?Cb??"????W'?B?FV??F?f?&???f??F????FW'2??'????w??B???V????7F?6?V?7G'?f?"'&V7B6&6?????????V????7F?6?V??????'????##?#?b??S3?SC"???????R?????4"?WB??F?66?&F?6R&WGvVV???7F?2????????6R7FGW2??&??'?????6????6V???V?r6?6W'2?BF?V?"6?'&W7??F??r?WF7F6W2???7F?F????w??#3?c"?"??3R?3B?????????2?"?6??R???WB??FWFV7F????b?vV?R&V'&?vV?V?B??????6???6V???V?r6?6W"??F??&2??6???#?b????3S??3cb????W2?&?????6???'?FV6???VW2??F?&V7B?6?V"7?&FR6?FW3?6?v??f?6?BWf??WF???f?"7?F?F????w?FV6???VW2?6?6W"7?F?F????#3?#?2??#?#?????gV?V????W&?V?2??V??V???R??WB??T??B??gW6???vV?R?BVff?67??b?????6R??&?F?"???V?r6?6W"?6??6?6W"&W2?#??B?2??C#sR?C#?2??v?R?&?r???6?FvRE"?WB????7F?2????????6R??&?F?????????6????6V???V?r6?6W"??V?v???VB?#?3c2????c?2?s2???G\:???V?2?&?WVWGFR??&VwVW&WB??WB??g&V?6??V?F?6V?G&?2?B&?7V7F?fRf?FF???7GVG?f?"?G&?6??6F???F?v??6?2???V?rFV??6&6????2?6????6???#3?3???#7W?V?V?B????ƒB??V?r????6?2?v?F&E"?vV??G???r?BvV???2&?f???r?b????6????6V???V?r6?6W#????6F???2f?"7W'&V?B?BgWGW&RF?W&?W2??6????6???#3?3?3??C??ƒ??ƒ????rB?WB??6???6?6?v??f?6?6R?bT??B??gW6???vV?R?B76?6?F???v?F?Tte"?B?$2vV?R?WFF???2??#?6???W6RF?V?G2v?F?????6???6V???V?r6?6W"???2??R?#3?????SS#?2???R?ƒ??wV???WB??W???'&?&?f???rFWFV7G2T??B??gW6?????'&V7B?6???&V7F???B????6???6V???V?r6?6W'2????6?6W"&W2?#??s?Ccb?Csb???FV????6v?RB?&V6?W??"?WB?????V7V?"FW7F??rwV?FV??Rf?"6V?V7F????b?V?r6?6W"F?V?G2f?"Tte"?B?G?&?6??R???6R??&?F?'3?wV?FV??Rg&??F?R6???VvR?b?W&?6?F????v?7G2???FW&?F????76?6?F???f?"F?R7GVG??b?V?r6?6W"??B76?6?F???f?"???V7V?"F????w???F??&2??6???#3???r???#2?S???6??B?6V??WGF????V?V?6??"?WB???FV?F?f?6F????b?Wr??B$UBvV?RgW6???2g&??6???&V7F??B?V?r6?6W"&??6?W2??GW&R?VB?##???3?"?3?B??&?????D???V?rB?WB???V?F??W?VBvV?RW?&W76????BgW6???G&?67&?B??6?2F?FWFV7B?gW6???2???V?r6?6W"?????V2F?r?#3?S?S?c?????F???242???6??6???2?WB??7V'G???r?bV?F?ffW&V?F?FVB????6???6V??6&6????2??'&??6???&??7?7V6??V?2??F??&2??6???#?R?B??CC"?CCr???W2??&66??4R???7F?2????????6RvV?R&V'&?vV?V?B??????6????6V???V?r6?6W"??'&?????V?F????6???72?6?V????##?cs??CR?Cr??????F?WV6????T??B??gW6??????V?r??WGFW%????F????#?sb?2??SS"?SS2??&6?WGF??&F????????GF???WB??&V6???V?FF???2f?"F?R??6?2?b?vV?R&V'&?vV?V?G2??????6???6V???V?r6?6W#?6??6V?7W2?bF?R?F??76?6?F????b?VF?6???6???w??BF?R?F??6?6?WG??bF????w??B7?F?F????w???F??&2??6???#3???2??3S"?3S???'FV?ƒ??6????r??W&??FW???WB??T??B??&V'&?vV?V?B??????6???6V???V?r6?6W"?B????GV??"?V?rF?77VW2???F????#??sB?"??cc?cs?